London, 2025 — Claritas Intelligence has published its latest market study on the global protein gel macromolecular imagers market, estimating the market at USD 1.10 billion in 2025 and projecting, under the firm's base case, a rise to USD 1.82 billion by 2033 at a 6.4% CAGR over the 2026–2033 forecast period.
The headline growth story is driven by three converging forces: the accelerating biologics pipeline, the codification of extracellular vesicle (EV) characterization workflows, and on-device AI integration that is expanding the addressable ASP range at the high end of the market. Biologics development — spanning monoclonal antibodies, ADCs, and cell and gene therapies — demands protein-level visualization at every stage from target identification through lot-release QC, sustaining instrument procurement cycles across pharma and academic labs alike. On the EV front, the MISEV2023 consensus guidelines, which accumulated 3,383 citations in 2024 alone, have codified Western blot confirmation of tetraspanin and cargo protein markers as a standard characterization step; as EV-based drug delivery programs advance toward IND filings, instrument procurement in this sub-vertical is expected to follow. Neurodegenerative disease biomarker research adds a further demand layer: a hallmarks-of-neurodegeneration framework review published in Cell (1,579 citations, 2023) has given structural coherence to Alzheimer's, Parkinson's, and ALS programs that depend heavily on protein aggregation assays and gel visualization.
At the device-type level, fluorescence multi-channel systems are the fastest-growing sub-segment, with the report projecting an 8.1% CAGR through 2033 as labs retire older chemiluminescence-only platforms in favour of multiplexed workflows. That migration is also reflected in the broader publication signal: 17,966 academic works indexed on protein gel macromolecular imaging since 2023 confirm a sustained bench-level dependency that ultimately converts to capital equipment orders, even as the installed base bifurcates between high-end fluorescence systems and sticky-but-declining legacy chemiluminescence documentation units. AI-driven capabilities, including CNN-based band detection and auto-exposure with quality scoring, are also clearing the bar for FDA 21 CFR Part 11-compliant GMP environments, which matters for ASP expansion at the premium tier.
North America holds the largest revenue share at approximately 38%, anchored by well-capitalized pharma and academic research infrastructure. Asia Pacific is the fastest-growing region, with Chinese government biotech stimulus and South Korean life science capital expenditure serving as the primary demand accelerants. The competitive landscape is led by Bruker Corporation (FY2025 revenue USD 3.44B), Bio-Rad Laboratories (FY2025 revenue USD 2.58B), and Thermo Fisher Scientific (FY2025 revenue USD 44.56B), alongside Danaher Corporation (Cytiva), PerkinElmer (Revvity), Shimadzu, TECAN, Analytik Jena, LI-COR Biosciences, Azure Biosystems, Syngene International, and Gel Doc Corporation.
The report also flags a structural risk that the report argues is under-priced in most market assessments. Thermo Fisher's deepening reagent-instrument bundling strategy is compressing stand-alone imager ASPs by an estimated 3–5% per year in Claritas's downside scenario, as iBright and Invitrogen-branded systems are increasingly subsidized by reagent margin and subscription service contracts.
"The proteomics volume story is real, but it obscures a bifurcation that matters for competitive positioning. Fluorescence multiplexing and AI-assisted analysis are expanding the premium tier, while legacy chemiluminescence accounts remain sticky only through consumable dependency — not hardware refreshes. Vendors that cannot credibly participate in both the reagent ecosystem and the software layer face a narrowing window." — Saurabh Shetty, Claritas Intelligence
About Claritas Intelligence: Claritas Intelligence is a global market intelligence publisher delivering deep-dive quantitative research across technology, life sciences, and industrial sectors. The firm's studies combine primary source triangulation, financial filing analysis, and proprietary modelling to support strategy teams, investors, and commercial leaders.
The full analysis, including segmentation, regional breakdowns, forecasts, and company profiles, is available in the Protein Gel Macromolecular Imagers Market Report.
“The global protein gel macromolecular imagers market is estimated at USD 1.10B in 2025 and the report projects USD 1.82B by 2033 at a 6.4% CAGR, driven by proteomics spend and EV research.”
Saurabh Shetty
Team Lead – Semiconductor & Electronic